Cohance Lifesciences Nacharam facility gets OAI status from USFDA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-10-27 06:08 GMT | Update On 2025-10-27 06:08 GMT

Mumbai: Cohance Lifesciences has announced that the Company has received report from the United States Food and Drug Administration (USFDA), determining the inspection classification of Finished Dosage Formulations Manufacturing Facility (FDF Unit-I) located in Nacharam, Hyderabad as “Official Action Indicated (OAI)”.

The Company is engaging proactively with the USFDA and has initiated a comprehensive remediation program and align the facility fully with global standards.

The FDF Unit -1 facility at Nacharam continues to run its operations normally.

Further, as intimated and clarified by Cohance on September 18, 2025, it reiterated that in FY2025, the US revenue from this formulation unit located at Nacharam contributed less than 2% of the Company’s consolidated revenues and with related EBITDA contribution below 1%. Therefore, it is not expected to have any material impact on the Company’s ongoing operations or supplies.

"We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets," the company stated in a BSE filing.

The Good Manufacturing Practices (GMP) inspection was conducted from August 4, 2025 to August 12, 2025 excluding the weekend of August 9 and 10, 2025. Intially, in August, the Company received a Form 483 from the USFDA with 06 observations.

Cohance Lifesciences is a technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. The company has over 100 active projects and a pipeline of late-stage molecules.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Cohance Lifesciences Nacharam facility gets OAI status from USFDA

Similar News

HLL is reliable hand in Medical Health Services: JP Nadda

Novartis to acquire Avidity Biosciences for USD 12 billion

Moderna scraps mRNA vaccine in congenital CMV on trial failure

India to Regulate Cell and Gene Therapies Under Drug Licensing Rules

Roche appoints Nina Schwab-Hautzinger as Head of Group Communications

Lilly to buy Adverum Biotechnologies

Dr Reddy's Labs assigns additional responsibilities of CHRO office to Sanjay Sharma